Short-term complications of type 1 diabetes are usually related to your blood glucose levels (BGLs) falling out of the targeted range your healthcare team has set for you. (jdrf.org.au)
Managing your blood glucose levels on a daily basis can be a delicate balancing act. (jdrf.org.au)
Hyperglycaemia is the opposite to hypoglycemia: it happens when your blood glucose levels are too high and there's not enough insulin in your body to bring down your BGLs. (jdrf.org.au)
Intensified therapy and maintaining near-normal blood glucose levels can result in considerable reduction in the risk of development of retinopathy, nephropathy and neuropathy. (who.int)
Insulin6
However, treatment with common therapies such as insulin or insulinotrophic sulphonylureas (SU), while effective in reducing hyperglycaemia, may impose a greater risk of hypoglycaemia, as neither therapy is self-regulated by ambient blood glucose concentrations. (nih.gov)
Stimulation of insulin secretion from pancreatic β-cells by glucagon-like peptide 1 receptor (GLP-1R) agonists is known to be glucose-dependent. (nih.gov)
GLP-1R agonists potentiate glucose-stimulated insulin secretion and have little or no activity on insulin secretion in the absence of elevated blood glucose concentrations. (nih.gov)
This review aims to discuss the current understanding of the mechanisms by which GLP-1R signalling promotes insulin secretion from pancreatic β-cells via a glucose-dependent process. (nih.gov)
It's normal to have hyperglycaemia when you're living with type 1 diabetes, and it's something that's usually managed with insulin. (jdrf.org.au)
DKA occurs because your body can't produce insulin, and if your blood glucose rises without enough insulin on board to bring your levels back to normal, your body starts to break down fat as fuel. (jdrf.org.au)
Diabetes3
The major goal in the treatment of type 2 diabetes mellitus is to control the hyperglycaemia characteristic of the disease. (nih.gov)
Recent upswings in the use of continuous glucose monitoring (CGM) technologies have given people with diabetes and healthcare professionals unprecedented access to a range of new indicators of glucose control. (springer.com)
When the Diabetes Control and Complications Trial (DCCT) first demonstrated that intensive glucose lowering reduces the risk of long-term diabetes complications, intensive glucose control involved self-monitoring of blood glucose (SMBG) at least four times daily, a weekly blood glucose check at 03:00 hours and regular laboratory measurement of HbA 1c [ 1 ]. (springer.com)
Clinical1
This hypothesis is supported by clinical studies showing that the majority of events of hypoglycaemia in patients treated with GLP-1R agonists occur in patients treated with a concomitant SU. (nih.gov)
Levels1
This should return to normal once you get your glucose levels stable again. (jdrf.org.au)
Risk2
hence minimization of hypoglycaemia risk is clinically advantageous. (nih.gov)
Some of these metrics are useful research tools and others have been welcomed by patient groups for providing insights into the quality of glucose control not captured by conventional laboratory testing. (springer.com)
Today, over a quarter of a century on, emphases on individualised care and advances in glucose monitoring technology have provided access to a wealth of alternative indices of glucose control quality that are available to individuals who have the means and desire to make use of continuous glucose monitoring (CGM) technologies. (springer.com)
Patients1
However, for clinicians and researchers who are most familiar with evidence supported by blood glucose measurement and HbA 1c , it may be difficult to know how to interpret TIR, where to position TIR relative to other glucose metrics and what TIR goals to discuss with patients. (springer.com)
Time1
In this short review, I summarise the state-of-the-art for TIR, emphasising that TIR is largely determined by the extent of hyperglycaemia and that any discussions around TIR goals should include consideration of time below range (TBR) as well. (springer.com)
To examine the impact of hypoglycaemia in insulin-treated patients in the Lebanese cohort of the Hypoglycaemia Assessment Tool (HAT) study. (who.int)
Blood Glucose1
In the past, assessment of glycemic control was primarily based on A1C measurement ( 1 - 3 ) and self-monitoring of blood glucose (SMBG) ( 4 , 5 ). (diabetesjournals.org)
Severe4
To assess the risks of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia in patients with type 2 diabetes associated with prescribed diabetes drugs, particularly newer agents including gliptins or glitazones (thiazolidinediones). (nih.gov)
Rates of nocturnal and severe hypoglycaemia were 10.7 (95% CI: 9.1-12.3) and 13.2 (95% CI: 11.5-14.9) events/patient-year for T1DM, and 3.3 (95% CI: 2.8-3.8) and 4.2 events/patient-year (95% CI: 3.6-4.8) for T2DM, respectively. (who.int)
Fear of hypoglycaemia was significantly associated with nocturnal and severe hypoglycaemia in both diabetes types (P (who.int)
However, different studies have shown an association between insulin therapy and increased risk of hypoglycaemia (4,5), in which 25-30% of insulin-treated patients with diabetes had 1 or more severe hypoglycaemic episodes every year (6). (who.int)
Complications1
A1C as a measure of mean glucose levels over the past 8-12 weeks is a good predictor of long-term complications but fails to capture the day-to-day experiences of glucose management ( 6 ). (diabetesjournals.org)
Levels3
During the exercise, the respiratory responses and glucose levels were monitored. (nih.gov)
The results suggest that the less-advanced healthcare systems in Lebanon are implicated in lower levels of patient knowledge about hypoglycaemia and related preventive measures. (who.int)
Hypoglycaemia affects medication adherence, patients' productivity (11), and quality of life at the mental, physical and social functioning levels (12). (who.int)